RecruitingNCT07093801
Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Real-world Experience of Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, National, Multicenter, Prospective Cohort Study (PLU4REAL).
Sponsor
Novartis Pharmaceuticals
Enrollment
300 participants
Start Date
Jul 30, 2025
Study Type
OBSERVATIONAL
Summary
This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 99 Years
Inclusion Criteria3
- Adult patients diagnosed with mCRPC eligible for and prescribed with lutetium (177Lu) vipivotide tetraxetan by the treating physician (Multidisciplinary Team).
- ≥ 18 years old at the time of enrollment.
- Written informed consent must be obtained to participate to this study
Locations(32)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07093801